Hematopoietic stem cell transplantation (HSCT) includes the administration of healthy hematopoietic stem cells to patients with damaged or defective bone marrow or immune stem. HSCT was first explored in the 1950s and was based on observational data in mice models which showed that infusion of healthy bone marrow components into a myelosuppressed bone marrow could induce recovery of its function in the recipient. The clinical application of this led the physicians to receive the Nobel Prize in physiology and medicine. Since then, HSCTs have gained attention worldwide and are now accepted as the standard care for hematologic malignancies, congenital or acquired disorders of hematopoietic systems, some solid tumours, and autoimmune and inherited metabolic disorders. The Center for International Blood and Marrow Transplant Research (CIBMTR) reported over 8000 allogenic and 11000 autologous transplants performed in the United States in 2021. HSCT is a highly specialized and unique medical procedure with various steps.
HSCT has evolved in its technology over 50 years and expanded worldwide. The procedure is performed by qualified medical staff in a facility with adequate conditions, the patient follow-up requires qualified management by a multidisciplinary team. Today, the increased number of unrelated donor transplantations promoted worldwide international collaborations, and extended donor availability is detected by high-resolution typing techniques. Haploidentical transplantation is becoming more prominent following successful results in many different indications. Research has focused on strategies to improve response rates while minimizing complications. In recent years, tremendous efforts put to identify the properties of hematopoietic stem cells, immunobiology of transplantation, and optimized grafts based on different graft sources. In this research topic, our goal is to show the recent advances and novel approaches in the field of HSCT.
Specific themes for this research topic:
1.Trends in new indications for HSCT (autologous/allogeneic, investigational)
2. Various facts of conditioning regimen (Intensity, toxicity, novel approaches, immunotherapy aspects)
3. High resolution donor typing techniques (next-generation sequencing), donor registries-Mismatched donor transplantations
4. Advantages and disadvantages of different stem sources (umbilical cord, bone marrow, peripheral blood)
5. Updates on apheresis, mobilization and collection of stem cells
6. Graft manipulations-vaccinations against tumour-associated antigens, monoclonal antibodies, targeted adoptive cellular immunotherapy (CAR T cells etc)
7. Novel post-transplant complication management strategies: Graft vs host disease, infections, hemorrhagic cystitis, sinusoidal obstruction syndrome, idiopathic pneumonia syndrome, graft rejection etc
8. HSCT basics: Immunological background, properties of HSC
9. Artificial intelligence in transplantation
Hematopoietic stem cell transplantation (HSCT) includes the administration of healthy hematopoietic stem cells to patients with damaged or defective bone marrow or immune stem. HSCT was first explored in the 1950s and was based on observational data in mice models which showed that infusion of healthy bone marrow components into a myelosuppressed bone marrow could induce recovery of its function in the recipient. The clinical application of this led the physicians to receive the Nobel Prize in physiology and medicine. Since then, HSCTs have gained attention worldwide and are now accepted as the standard care for hematologic malignancies, congenital or acquired disorders of hematopoietic systems, some solid tumours, and autoimmune and inherited metabolic disorders. The Center for International Blood and Marrow Transplant Research (CIBMTR) reported over 8000 allogenic and 11000 autologous transplants performed in the United States in 2021. HSCT is a highly specialized and unique medical procedure with various steps.
HSCT has evolved in its technology over 50 years and expanded worldwide. The procedure is performed by qualified medical staff in a facility with adequate conditions, the patient follow-up requires qualified management by a multidisciplinary team. Today, the increased number of unrelated donor transplantations promoted worldwide international collaborations, and extended donor availability is detected by high-resolution typing techniques. Haploidentical transplantation is becoming more prominent following successful results in many different indications. Research has focused on strategies to improve response rates while minimizing complications. In recent years, tremendous efforts put to identify the properties of hematopoietic stem cells, immunobiology of transplantation, and optimized grafts based on different graft sources. In this research topic, our goal is to show the recent advances and novel approaches in the field of HSCT.
Specific themes for this research topic:
1.Trends in new indications for HSCT (autologous/allogeneic, investigational)
2. Various facts of conditioning regimen (Intensity, toxicity, novel approaches, immunotherapy aspects)
3. High resolution donor typing techniques (next-generation sequencing), donor registries-Mismatched donor transplantations
4. Advantages and disadvantages of different stem sources (umbilical cord, bone marrow, peripheral blood)
5. Updates on apheresis, mobilization and collection of stem cells
6. Graft manipulations-vaccinations against tumour-associated antigens, monoclonal antibodies, targeted adoptive cellular immunotherapy (CAR T cells etc)
7. Novel post-transplant complication management strategies: Graft vs host disease, infections, hemorrhagic cystitis, sinusoidal obstruction syndrome, idiopathic pneumonia syndrome, graft rejection etc
8. HSCT basics: Immunological background, properties of HSC
9. Artificial intelligence in transplantation
